Claims for Patent: 8,986,935

Summary for Patent: 8,986,935

Title:	Methods for treating spinal muscular atrophy
Abstract:	Described herein are methods for the identification or validation of compounds capable of causing ribosomal frameshifting and the use of the compounds identified by the methods described herein to produce a stabilized SMN.DELTA.Ex7 protein and treat Spinal Muscular Atrophy.
Inventor(s):	Paushkin; Sergey V. (Belle Mead, NJ), Naryshkin; Nikolai A. (East Brunswick, NJ), Welch; Ellen (Califon, NJ)
Assignee:	PTC Therapeutics, Inc. (South Plainfield, NJ)
Application Number:	13/058,653
Patent Claims:	1. A method for the identification of a compound that produces a stabilized SMN.DELTA.Ex7 protein comprising: (A) contacting a compound with either a host cell containing an mRNA transcript transcribed from a nucleic acid construct, or a composition comprising a cell-free extract and an mRNA transcript transcribed from a nucleic acid construct, wherein the nucleic acid construct comprises, in 5' to 3' order: (a) a start codon; (b) a fragment of the nucleic acid residues of exon 8 of SMN; and (c) a reporter gene coding sequence lacking a start codon, wherein (i) the reporter gene coding sequence is fused to the fragment of the nucleic acid residues of exon 8 of SMN such that the first codon of the reporter gene coding sequence and the first codon of the fragment are out of frame with each other in the mRNA transcript transcribed from the nucleic acid construct and a stop codon is upstream of the reporter gene coding sequence in the mRNA transcript; and (ii) the start codon and the stop codon upstream of the reporter gene coding sequence in the mRNA transcript are in the same contiguous open reading frame; (B) detecting the activity or amount of a fusion protein translated from the mRNA transcript, wherein an increase in the activity or amount of the fusion protein translated from the mRNA transcript in the presence of a compound when compared to: (i) a previously determined reference range for a negative control, (ii) the activity or amount of the fusion protein translated from the mRNA transcript in the absence of the compound, or (iii) the activity or amount of the fusion protein translated from the mRNA transcript in the presence of a negative control indicates that the compound produces a stabilized SMN.DELTA.Ex7 protein; and (C) contacting a compound that increases the activity or amount of the fusion protein translated from the mRNA transcript with a cell that produces SMN.DELTA.Ex7 protein and assaying the ability of the compound to increase the level of stabilized SMN.DELTA.Ex7 protein in the cell in the presence of the compound as compared to the level of SMN.DELTA.Ex7 protein in the cell in the presence of the compound, wherein an increase in the level of stabilized SMN.DELTA.Ex7 protein relative to the level of SMN.DELTA.Ex7 protein indicates that a compound that produces a stabilized SMN.DELTA.Ex7 protein is identified, wherein said stabilized SMN.DELTA.Ex7 protein comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5. 2. The method of claim 1, wherein the nucleic acid construct comprises a fragment of the nucleic acid residues of exon 7 of SMN downstream (3') of the start codon and upstream (5') of the fragment of the nucleic acid residues of exon 8 of SMN, and wherein the fragment of the nucleic acid residues of exon 7 of SMN comprises any number of nucleotides of exon 7 of SMN so long as in the mRNA transcript the start codon and the stop codon upstream of the reporter gene coding sequence are maintained in the same contiguous open reading frame. 3. A method for the identification of a compound that produces a stabilized SMN.DELTA.Ex7 protein comprising: (A) contacting a compound with either a host cell containing an mRNA transcript transcribed from a nucleic acid construct, or a composition comprising a cell-free extract and an mRNA transcript transcribed from a nucleic acid construct, wherein the nucleic acid construct comprises, in 5' to 3' order: (a) a start codon; (b) the nucleic acid residues of exon 7 of SMN, wherein any number of nucleotides are inserted after the 48.sup.th nucleotide residue from the 5' end of exon 7 of SMN as long as the native stop codon of exon 7 of SMN is inactivated and any additional stop codon is not generated; (c) a fragment of the nucleic acid residues of exon 8 of SMN; and (d) a reporter gene coding sequence lacking a start codon, wherein: (i) the reporter gene coding sequence is fused to the fragment of the nucleic acid residues of exon 8 of SMN such that the first codon of the reporter gene coding sequence and the first codon of the fragment are out of frame with each other in the mRNA transcript transcribed from the nucleic acid construct and there is a stop codon upstream of the reporter gene coding sequence in the region of the mRNA transcript that corresponds to the fragment of the nucleic acid residues of exon 8 of SMN; and (ii) the start codon and the stop codon upstream from the reporter gene coding sequence in the mRNA transcript are in the same contiguous open reading frame; (B) detecting the activity or amount of a fusion protein translated from the mRNA transcript, wherein an increase in the activity or amount of the fusion protein translated from the mRNA transcript in the presence of a compound when compared to: (i) a previously determined reference range for a negative control, (ii) the activity or amount of the fusion protein translated from the mRNA transcript in the absence of the compound, or (iii) the activity or amount of the fusion protein translated from the mRNA transcript in the presence of a negative control indicates that the compound produces a stabilized SMN.DELTA.Ex7 protein; and (C) contacting a compound that increases the activity or amount of the fusion protein translated from the mRNA transcript with a cell that produces SMN.DELTA.Ex7 protein and assaying the ability of the compound to increase the level of stabilized SMN.DELTA.Ex7 protein in the cell in the presence of the compound as compared to the level of SMN.DELTA.Ex7 protein in the cell in the presence of the compound, wherein an increase in the level of stabilized SMN.DELTA.Ex7 protein relative to the level of SMN.DELTA.Ex7 protein indicates that a compound that produces a stabilized SMN.DELTA.Ex7 protein is identified, wherein said stabilized SMN.DELTA.Ex7 protein comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5. 4. The method of claim 3, wherein: (a) the nucleic acid construct comprises the nucleic acid residues of exon 6 of SMN or a fragment thereof downstream (3') of the start codon and upstream (5') of the nucleic acid residues of exon 7 of SMN, wherein the fragment of the nucleic acid residues of exon 6 of SMN comprises any number of nucleotides of exon 6 of SMN so long as in the mRNA transcript the start codon and the stop codon upstream of the reporter gene coding sequence are maintained in the same contiguous open reading frame; or (b) the nucleic acid construct comprises the nucleic acid residues of intron 7 of SMN or a fragment thereof downstream (3') of the nucleic acid residues of exon 7 of SMN and upstream (5') of the fragment of the nucleic acid residues of exon 8 of SMN, wherein the fragment of the nucleic acid residues of intron 7 comprises any number of nucleotides of intron 7 of SMN required for a functional, minimum intron. 5. A method for the identification of a compound that produces a stabilized SMN.DELTA.Ex7 protein comprising: (A) contacting a compound with either a host cell containing an mRNA transcript transcribed from a nucleic acid construct, or a composition comprising a cell-free extract and an mRNA transcript transcribed from a nucleic acid construct, in 5' to 3' order: (a) a start codon; (b) the nucleic acid residues of exon 7 of SMN, wherein a single guanine residue is inserted after the 48.sup.th nucleotide residue from the 5' end of exon 7 of SMN; (c) the nucleic acid residues of intron 7 of SMN or a fragment thereof, wherein the fragment of the nucleic acid residues of intron 7 comprises any number of nucleotides of intron 7 of SMN required for a functional, minimum intron; (d) a fragment of the nucleic acid residues of exon 8 of SMN; and (e) a reporter gene coding sequence lacking a start codon, wherein: (i) the reporter gene coding sequence is fused to the fragment of the nucleic acid residues of exon 8 of SMN such that the first codon of the reporter gene coding sequence and the first codon of the fragment are out of frame with each other in the mRNA transcript transcribed from the nucleic acid construct; and (ii) the production of the mRNA transcript generates a stop codon upstream from the reporter gene coding sequence in the region of the mRNA transcript that corresponds to the fragment of the nucleic acid residues of exon 8 of SMN; and (iii) the start codon and the stop codon upstream from the reporter gene coding sequence in the mRNA transcript are in the same contiguous open reading frame; (B) detecting the activity or amount of a fusion protein translated from the mRNA transcript, wherein an increase in the activity or amount of the fusion protein translated from the mRNA transcript in the presence of a compound when compared to: (i) a previously determined reference range for a negative control, (ii) the activity or amount of the fusion protein translated from the mRNA transcript in the absence of the compound, or (iii) the activity or amount of the fusion protein translated from the mRNA transcript in the presence of a negative control indicates that the compound produces a stabilized SMN.DELTA.Ex7 protein; and (C) contacting a compound that increases the activity or amount of the fusion protein translated from the mRNA transcript with a cell that produces SMN.DELTA.Ex7 protein and assaying the ability of the compound to increase the level of stabilized SMN.DELTA.Ex7 protein in the cell in the presence of the compound as compared to the level of SMN.DELTA.Ex7 protein in the cell in the presence of the compound, wherein an increase in the level of stabilized SMN.DELTA.Ex7 protein relative to the level of SMN.DELTA.Ex7 protein indicates that a compound that produces a stabilized SMN.DELTA.Ex7 protein is identified, wherein said stabilized SMN.DELTA.Ex7 protein comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5. 6. The method of claim 5, wherein the nucleic acid construct comprises the nucleic acid residues of exon 6 of SMN or a fragment thereof downstream (3') to the start codon and upstream (5') of the nucleic acid residues of exon 7 of SMN, wherein the fragment of the nucleic acid residues of exon 6 of SMN comprises any number of nucleotides of exon 6 of SMN so long as in the mRNA transcript the start codon and the stop codon upstream of the reporter gene coding sequence are maintained in the same contiguous open reading frame. 7. A method for the identification of a compound that produces a stabilized SMN.DELTA.Ex7 protein comprising: (A) contacting a compound with either a host cell containing an mRNA transcript transcribed from a nucleic acid construct, or a composition comprising a cell-free extract and an mRNA transcript transcribed from a nucleic acid construct, in 5' to 3' order: (a) a start codon; (b) a minimum of one nucleotide; (c) a fragment of the nucleic acid residues of exon 7 of SMN, wherein (i) the fragment of the nucleic acid residues of exon 7 of SMN comprises a minimum of the first six nucleotides from the 3' end of exon 7 of SMN and wherein a single guanine residue is inserted into the fragment of the nucleic acid residues of exon 7 of SMN at the location that corresponds to the location in exon 7 of SMN that is after the 48.sup.th nucleotide from the 5' end of exon 7 of SMN or (ii) the fragment of the nucleic acid residues of exon 7 of SMN consists of the first six nucleotides from the 3' end of exon 7 of SMN and wherein a single guanine residue is inserted upstream (5') of the fragment of the nucleic acid residues of exon 7 of SMN; (d) the nucleic acid residues of intron 7 of SMN or a fragment thereof, wherein the fragment of the nucleic acid residues of intron 7 of SMN comprises any number of nucleotides of intron 7 required for a functional, minimum intron; (e) a fragment of the nucleic acid residues of exon 8 of SMN; and (f) a reporter gene coding sequence lacking a start codon, wherein (i) the reporter gene coding sequence is fused to the fragment of the nucleic acid residues of exon 8 of SMN such that the first codon of the reporter gene coding sequence and the first codon of the fragment are out of frame with each other in the mRNA transcript transcribed from the nucleic acid construct; and (ii) the production of the mRNA transcript generates a stop codon upstream from the reporter gene coding sequence in the region of the mRNA transcript that corresponds to the fragment of the nucleic acid residues of exon 8 of SMN; and (iii) the start codon and the stop codon upstream from the reporter gene coding sequence in the mRNA transcript are in the same contiguous open reading frame; (B) detecting the activity or amount of a fusion protein translated from the mRNA transcript, wherein an increase in the activity or amount of the fusion protein translated from the mRNA transcript in the presence of a compound when compared to: (i) a previously determined reference range for a negative control, (ii) the activity or amount of the fusion protein translated from the mRNA transcript in the absence of the compound, or (iii) the activity or amount of the fusion protein translated from the mRNA transcript in the presence of a negative control indicates that the compound produces a stabilized SMN.DELTA.Ex7 protein; and (C) contacting a compound that increases the activity or amount of the fusion protein translated from the mRNA transcript with a cell that produces SMN.DELTA.Ex7 protein and assaying the ability of the compound to increase the level of stabilized SMN.DELTA.Ex7 protein in the cell in the presence of the compound as compared to the level of SMN.DELTA.Ex7 protein in the cell in the presence of the compound, wherein an increase in the level of stabilized SMN.DELTA.Ex7 protein relative to the level of SMN.DELTA.Ex7 protein indicates that a compound that produces a stabilized SMN.DELTA.Ex7 protein is identified, wherein said stabilized SMN.DELTA.Ex7 protein comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5. 8. The method of claim 7, wherein the nucleic acid construct comprises the nucleic acid residues of exon 6 of SMN or a fragment thereof downstream (3') to the start codon and upstream (5') of the nucleic acid residues of exon 7 of SMN, wherein the fragment of the nucleic acid residues of exon 6 of SMN comprises any number of nucleotides of exon 6 of SMN so long as in the mRNA transcript the start codon and the stop codon upstream of the reporter gene coding sequence are maintained in the same contiguous open reading frame. 9. The method of claim 8, wherein the nucleic acid construct comprises the nucleic acid residues of intron 6 of SMN or a fragment thereof downstream (3') of the nucleic acid residues of exon 6 of SMN or a fragment thereof and upstream (5') of the nucleic acid residues of exon 7 of SMN, wherein the fragment of the nucleic acid residues of intron 6 of SMN comprises any number of nucleotides of intron 6 of SMN required for a functional, minimum intron.

Details for Patent 8,986,935

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2028-08-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2028-08-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2028-08-13